Next |
home / stock / lxrx / lxrx message board
Subject | By | Source | When |
---|---|---|---|
whytestocks: $LXRX News Article - Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpet | whytestocks | investorshangout | 04/21/2023 4:35:49 PM |
Passing 2.69. | BooDog | investorshub | 04/17/2023 1:50:06 PM |
Let's get the move on. | BooDog | investorshub | 04/14/2023 2:51:12 PM |
PUDUFA coming in a couple months. Looks | BooDog | investorshub | 03/06/2023 2:36:59 PM |
znewcar1: $LXRX 22% v1,7M c2.68 f188,725M H2.85 ML2.13=RL | znewcar1 | investorshangout | 03/03/2023 10:04:33 PM |
znewcar1: $LXRX RL2.13 HOD2.72> V>800K | znewcar1 | investorshangout | 03/03/2023 5:29:12 PM |
$LXRX: Time to load July $3 calls...... now $0.70 | makinezmoney | investorshub | 03/03/2023 3:38:44 PM |
Chart showing some strength. Closes over 2.20 | BooDog | investorshub | 11/10/2022 3:44:05 PM |
Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its | BooDog | investorshub | 10/26/2022 2:48:49 PM |
Bears are on the job. eom | BooDog | investorshub | 09/16/2022 7:47:22 PM |
Bear flag forming. And right before the | BooDog | investorshub | 09/01/2022 1:41:24 PM |
Nice to see the volume maintaining. Hope some | BooDog | investorshub | 08/12/2022 3:44:28 PM |
Nice!! Get'r done $LXRX! | BooDog | investorshub | 08/10/2022 7:51:32 PM |
Watching the reset. Told you this a great | BooDog | investorshub | 07/18/2022 7:15:04 PM |
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price | BooDog | investorshub | 07/15/2022 1:45:15 PM |
This could push back over $4 before the | BooDog | investorshub | 07/12/2022 10:29:33 AM |
BooDog: $LXRX looks to be on the move | BooDog | investorshangout | 07/08/2022 10:50:40 AM |
znewcar1: LXRX 41% v27,5M c2.75 f149,6M H2.97 | znewcar1 | investorshangout | 07/05/2022 8:08:40 PM |
Awesome. For real. | BooDog | investorshub | 06/29/2022 9:08:00 PM |
We expect that the new joint guidelines issued | BooDog | investorshub | 04/19/2022 10:24:27 AM |
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease Company Anticipates Six Month Review and Potential Launch in Early 2025 THE WOODLANDS, Texas, June 21, 2024 (GLOBE NEWSWIR...
Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP) Investigators conclude that clinical outcomes of RELIEF-DPN 1 support commencement of Lexiconȁ...
New analysis of the pivotal Phase 3 SOLOIST-WHF trial demonstrates INPEFA cost-effectiveness Findings consistent with another study recently published in the Journal of Comparative Effectiveness Research THE WOODLANDS, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pha...